BACKGROUND: The Cognitive Behavioral Analysis System of Psychotherapy (CBASP), initially developed as an outpatient treatment for chronic depression (CD), has been adapted as a multidisciplinary 12-week inpatient program for CD. METHODS: Seventy inpatients with CD and treatment resistance were included in a noncontrolled trial. The Hamilton Depression Rating Scale served as the primary outcome measure. Prospective naturalistic follow-up assessments were conducted 6 and 12 months after discharge. RESULTS: Dropout rate was 7.1%; 90.4% perceived the program as helpful. Pre-post comparisons yielded strong effect sizes; 75.7% of the intention-to-treat sample responded, and 40.0% remitted. Nonremission was associated with experiencing temporary deterioration of symptoms during treatment. After 6 months 75.0% and after 12 months 48.0% of patients sustained response. CONCLUSIONS: The CBASP program appears as a feasible acute treatment for treatment-resistant CD inpatients with promising outcome. However, the continuation of treatment after discharge should be optimized especially for patients with subjective deterioration during treatment.
BACKGROUND: The Cognitive Behavioral Analysis System of Psychotherapy (CBASP), initially developed as an outpatient treatment for chronic depression (CD), has been adapted as a multidisciplinary 12-week inpatient program for CD. METHODS: Seventy inpatients with CD and treatment resistance were included in a noncontrolled trial. The Hamilton Depression Rating Scale served as the primary outcome measure. Prospective naturalistic follow-up assessments were conducted 6 and 12 months after discharge. RESULTS: Dropout rate was 7.1%; 90.4% perceived the program as helpful. Pre-post comparisons yielded strong effect sizes; 75.7% of the intention-to-treat sample responded, and 40.0% remitted. Nonremission was associated with experiencing temporary deterioration of symptoms during treatment. After 6 months 75.0% and after 12 months 48.0% of patients sustained response. CONCLUSIONS: The CBASP program appears as a feasible acute treatment for treatment-resistant CD inpatients with promising outcome. However, the continuation of treatment after discharge should be optimized especially for patients with subjective deterioration during treatment.
Authors: Sagar V Parikh; Lena C Quilty; Paula Ravitz; Michael Rosenbluth; Barbara Pavlova; Sophie Grigoriadis; Vytas Velyvis; Sidney H Kennedy; Raymond W Lam; Glenda M MacQueen; Roumen V Milev; Arun V Ravindran; Rudolf Uher Journal: Can J Psychiatry Date: 2016-08-02 Impact factor: 4.356
Authors: K Schnell; A Hochlehnert; M Berger; J Wolff; M Radtke; E Schramm; C Normann; S C Herpertz Journal: Nervenarzt Date: 2016-03 Impact factor: 1.214
Authors: Stuart J Eisendrath; Erin Gillung; Kevin L Delucchi; Zindel V Segal; J Craig Nelson; L Alison McInnes; Daniel H Mathalon; Mitchell D Feldman Journal: Psychother Psychosom Date: 2016-01-26 Impact factor: 17.659
Authors: Philip Negt; Eva-Lotta Brakemeier; Johannes Michalak; Lotta Winter; Stefan Bleich; Kai G Kahl Journal: Brain Behav Date: 2016-05-03 Impact factor: 2.708
Authors: Manal E Alkahtani; Alhassan H Aodah; Omar A Abu Asab; Abdul W Basit; Mine Orlu; Essam A Tawfik Journal: Pharmaceutics Date: 2021-06-16 Impact factor: 6.321